eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
4/2018
vol. 14
 
Share:
Share:
more
 
 
abstract:
Experimental research

Pretreatment with obestatin inhibits the development of acetic acid-induced colitis in rats

Aleksandra Matuszyk, Piotr Ceranowicz, Zygmunt Warzecha, Jakub Cieszkowski, Krystyna Gałązka, Joanna Bonior, Jolanta Jaworek, Peter Christopher Konturek, Krzysztof Gil, Artur Dembiński

Arch Med Sci 2018; 14, 4: 920–929
Online publish date: 2016/03/23
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Obestatin is a 23-amino acid peptide derived from proghrelin, a common prohormone for ghrelin and obestatin. Previous studies have shown that obestatin exhibits some protective and therapeutic effects in the pancreas and stomach. The aim of this study was to examine the effect of pretreatment with obestatin on the development of acetic acid-induced colitis.

Material and methods
Studies were performed on Wistar rats. Before induction of colitis, rats were treated intraperitoneally with saline or obestatin, administered twice at a dose of 4, 8 or 16 nmol/kg/dose. The first dose of saline or obestatin was administered 8 h before the induction of colitis, the second one 7 h after the first dose. Colitis was induced by enema with 1 ml of 4% acetic acid solution. The severity of colitis was assessed 1 or 24 h after administration of enema.

Results
Pretreatment with obestatin administered at a dose of 8 or 16 nmol/kg/dose significantly reduced the area of mucosal damage evoked by enema with acetic acid (p < 0.05). This effect was accompanied by an improvement of mucosal blood flow and DNA synthesis in the colon. Moreover, obestatin administered at a dose of 8 or 16 nmol/kg/dose significantly reduced mucosal concentration of IL-1β and activity of myeloperoxidase (p < 0.05).

Conclusions
Pretreatment with obestatin exhibited a protective effect in the colon, leading to a reduction of colonic damage in acetic acid-induced colitis. This effect was associated with an improvement of mucosal blood flow, an increase in mucosal cell proliferation, and a decrease in local inflammation.

keywords:

cell proliferation, blood flow, myeloperoxidase, interleukin-1β

references:
Stenson WF, Hanauer SB, Cohen RD. Inflammatory bowel disease. In: Textbook of gastroenterology. Fifth edition. Yamada T, Alpers DH, Kalloo AN, Kaplowitz N, Owyang C, Powell DW (eds). Wiley-Blackwell, Chichester 2009; 1386-472.
Tsironi E, Feakins RM, Probert CS, Rampton DS, Phil D. Incidence of inflammatory bowel disease is rising and abdominal tuberculosis is falling in Bangladeshis in East London, United Kingdom. Am J Gastroenterol 2004; 99: 1749-55.
Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54.
Ng SC, Bernstein CN, Vatn MH, et al. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut 2013; 62: 630-49.
Baumgart DC. The diagnosis and treatment of Crohn’s disease and ulcerative colitis. Dtsch Arztebl Int 2009; 106: 123-33.
Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet 2012; 380: 1590-605.
Zhang JV, Ren PG, Avsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin’s effects on food intake. Science 2005; 310: 996-9.
Ceranowicz P, Warzecha Z, Dembiński A. Peptidyl hormones of endocrine cells origin in the gut – their discovery and physiological relevance. J Physiol Pharmacol 2015; 66: 11-27.
Zizzari P, Longchamps R, Epelbaum J, et al. Obestatin partially affects ghrelin stimulation of food intake and growth hormone secretion in rodents. Endocrinology 2007; 148: 1648-53.
Dembiński A, Warzecha Z, Ceranowicz P, et al. Variable effect of ghrelin administration on pancreatic development in young rats. Role of insulin-like growth factor-1. J Physiol Pharmacol 2005; 56: 555-70.
Warzecha Z, Dembiński A. Protective and therapeutic effects of ghrelin in the gut. Curr Med Chem 2012; 19: 118-25.
Zhang JV, Ren PG, Vsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin’s effects on food intake. Science 2005; 310: 996-9.
Chen CY, Asakawa A, Fujimiya M, Lee SD, Inui A. Ghrelin gene products and the regulation of food intake and gut motility. Pharmacol Rev 2009; 61: 430-81.
Dembiński A, Warzecha Z, Ceranowicz P, et al. Administration of obestatin accelerates the healing of chronic gastric ulcers in rats. Med Sci Monit 2011; 17: BR196-200.
Pamukcu O, Kumral ZN, Ercan F, Yegen BC, Ertem D. Anti-inflammatory effect of obestatin and ghrelin in dextran sulfate sodium-induced colitis in rats. J Pediatr Gastroenterol Nutr 2013; 57: 211-8.
Ceranowicz P, Warzecha Z, Dembinski A, et al. Pretreatment with obestatin inhibits the development of cerulein-induced pancreatitis. J Physiol Pharmacol 2009; 60: 95-101.
Bukowczan J, Warzecha Z, Ceranowicz P, Kuśnierz-Cabala B, Tomaszewska R, Dembinski A. Pretreatment with obestatin reduces the severity of ischemia/reperfusion-induced acute pancreatitis in rats. Eur J Pharmacol 2015; 760: 113-21.
Bukowczan J, Warzecha Z, Ceranowicz P, Kuśnierz-Cabala B, Tomaszewska R. Obestatin accelerates the recovery in the course of ischemia/reperfusion-induced acute pancreatitis in rats. PLoS One 2015; 10: e0134380.
Bukowczan J, Cieszkowski J, Warzecha Z, et al. A. Therapeutic effect of obestatin in the course of cerulein-induced acute pancreatitis. Pancreas 2015 Oct 15 [Epub ahead of print].
Granata R, Settanni F, Gallo D, et al. Obestatin promotes survival of pancreatic beta-cells and human islets and induces expression of genes involved in the regulation of beta-cell mass and function. Diabetes 2008; 57: 967-79.
Alexandridis E, Zisimopoulos A, Liratzopoulos N, Katsos I, Manolas K, Kouklakis G. Obestatin/ghrelin ratio: a new activity index in inflammatory bowel diseases. Inflamm Bowel Dis 2009; 15: 1557-61.
Jung JY, Jeong JB, Kim JW, et al. Circulating ghrelin levels and obestatin/ghrelin ratio as a marker of activity in ulcerative colitis. Intest Res 2015; 13: 68-73.
Warzecha Z, Ceranowicz P, Dembinski M, et al. Involvement of cyclooxygenase-1 and cyclooxygenase-2 activity in the therapeutic effect of ghrelin in the course of ethanol-induced gastric ulcers in rats. J Physiol Pharmacol 2014; 65: 95-106.
Dembiński A, Warzecha Z, Ceranowicz P, et al. Role of capsaicin-sensitive nerves and histamine H1, H2, and H3 receptors in the gastroprotective effect of histamine against stress ulcers in rats. Eur J Pharmacol 2005; 508: 211-21.
Warzecha Z, Dembiński A, Brzozowski T, et al. Gastroprotective effect of histamine and acid secretion on ammonia-induced gastric lesions in rats. Scand J Gastroenterol 2000; 35: 916-24.
Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982; 78: 206-9.
Vilaseca J, Salas A, Guarner F, Rodríguez R, Martínez M, Malagelada JR. Dietary fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis. Gut 1990; 31: 539-44.
Greant P, Delvaux G, Willems G. Influence of stress on epithelial cell proliferation in the gut mucosa of rats. Digestion 1988; 40: 212-8.
Hall PA, Coates PJ, Ansari B, Hopwood D. Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. J Cell Sci 1994; 107: 3569-77.
Konturek SJ, Dembiński A, Warzecha Z, Brzozowski T, Gregory H. Role of epidermal growth factor in healing of chronic gastroduodenal ulcers in rats. Gastroenterology 1988; 94: 1300-7.
Brzozowski T, Konturek PC, Konturek SJ, et al. Effect of local application of growth factors on gastric ulcer healing and mucosal expression of cyclooxygenase-1 and -2. Digestion 2001; 64: 15-29.
Beckert S, Class N, Farrahi F, Coerper S. Growth hormone enhances gastric ulcer healing in rats. Med Sci Monit 2004; 10: BR255-8.
Podolsky DK. Regulation of intestinal epithelial proliferation: a few answers, many questions. Am J Physiol 1993; 264: G179-86.
Sørbye H, Svanes K. The role of blood flow in gastric mucosal defence, damage and healing. Dig Dis 1994; 12: 305-17.
Warzecha Z, Kownacki P, Ceranowicz P, Dembinski M, Cieszkowski J, Dembinski A. Ghrelin accelerates the healing of oral ulcers in non-sialoadenectomized and sialoadenectomized rats. J Physiol Pharmacol 2013; 64: 657-68.
Orlando RC. The integrity of the esophageal mucosa. Balance between offensive and defensive mechanisms. Best Pract Res Clin Gastroenterol 2010; 24: 873-82.
Ceranowicz P, Warzecha Z, Dembiński A, et al. Treatment with ghrelin accelerates the healing of acetic acid-induced gastric and duodenal ulcers in rats. J Physiol Pharmacol 2009; 60: 87-98.
Leung FW, Su KC, Pique JM, Thiefin G, Passaro E Jr, Guth PH. Superior mesenteric artery is more important than inferior mesenteric artery in maintaining colonic mucosal perfusion and integrity in rats. Dig Dis Sci 1992; 37: 1329-35.
Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519-50.
Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012; 11: 633-52.
Choi AJ, Ryter SW. Inflammasomes: molecular regulation and implications for metabolic and cognitive diseases. Mol Cells 2014; 37: 441-8.
Nicklin MJ, Weith A, Duff GW. A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes. Genomics 1994; 19: 382-4.
Xiao M, Guo L, Wang T, et al. Interleukin-1B-31T/C promoter polymorphism and chronic obstructive pulmonary disease risk: a meta-analysis. Arch Med Sci 2014; 10: 434-8.
Ma L, Chu WM, Zhu J, Wu YN, Wang ZL. Interleukin-1beta (3953/4) CT polymorphism increases the risk of chronic periodontitis in Asians: evidence from a meta-analysis of 20 case-control studies. Arch Med Sci 2015; 11: 267-73.
Norman J, Franz M, Messina J, et al. Interleukin-1 receptor antagonist decreases severity of experimental acute pancreatitis. Surgery 1995; 117: 648-55.
Dinarello CA. A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur J Immunol 2011; 41: 1203-17.
De Koning HD, Schalkwijk J, van der Ven-Jongekrijg J, Stoffels M, van der Meer JW, Simon A. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler’s syndrome. Ann Rheum Dis 2013; 72: 1634-8.
Herlin T, Fiirgaard B, Bjerre M, et al. Efficacy of anti-IL-1 treatment in Majeed syndrome. Ann Rheum Dis 2013; 72: 410-3.
Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 2005; 77: 598-625.
Mullane KM, Kraemer R, Smith B. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods 1985; 14: 157-67.
FEATURED PRODUCTS
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe